Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease

Archives of Neurology

Volumn 53, Issue 12, 1996, Pages 1233-1238

  Zerr, Inga ^a   Helmhold, Marion ^a   Poser, Sigrid ^a   Armstrong, Victor W ^a   Weber, Thomas ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Marienkrankenhaus Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; IMMUNOGLOBULIN G; NEURON SPECIFIC ENOLASE; PRION PROTEIN; PROTEIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; ELECTROENCEPHALOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOELECTRIC FOCUSING; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030479067     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550120041014     Document Type: Article

References (37)

1. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90:8098-8102.
2. Namba Y, Ikeda K. Apolipoprotein B immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in senile dementia of Alzheimer type. Rinsho Shinkeigaku. 1991;31:826-830.
3. Poirier J. Apolipoprotein E in animal models of CNS injury and In Alzheimer's disease. Trends Neurosci. 1994;17:525-530.
4. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
5. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923
6. Galasko D, Saitoh T, Xia Y, et al. The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology. 1994;44:1950-1951.
7. Peacock ML, Fink JK. ApoE epsilon 4 allelic association with Alzheimer's disease: independent confirmation using denaturing gradient gel electrophoresis. Neurology. 1994;44:339-341.
8. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90: 9649-9653.
9. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
10. Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. Am J Hum Genet. 1980;32:339-347.
11. Menzel HJ, Kladetzky RG, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis. 1983;3:310-315.
12. Frisoni GB, Geroldi C, Bianchetti A, et al. Apolipoprotein E epsilon 4 allele frequency in vascular dementia and Alzheimer's disease. Stroke. 1994;25:1703-1704.
13. Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A. Protection against Alzheimer's disease with ApoE epsilon 2. Lancet. 1994;343:1432-1433.
14. Benjamin R, Leake A, McArthur FK, et al. Protective effect of ApoE epsilon 2 in Alzheimer's disease. Lancet. 1994;344:473.
15. Smith AD, Johnston C, Sim E, et al. Protective effect of Apo epsilon 2 in Alzheimer's disease: Oxford Project to Investigate Memory and Ageing (OPTIMA). Lancet. 1994;344:473-474.
16. Diedrich JF, Minnigan H, Carp RI, et al. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol. 1991;65:4759-4768.
17. Amouyel P, Vidal O, Launay J-M, Laplanche JL. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. Lancet. 1994;344: 1315-1318.
18. Nakagawa Y, Kitamoto T, Furukawa H, Ogomori K, Tateishi J. Apolipoprotein E in Creutzfeldt-Jakob disease. Lancet. 1995;345:68.
19. Zerr I, Helmhold M, Weber T, Armstrong VW. Apolipoprotein E in Creutzfeldt-Jakob disease. Lancet. 1944;345:68-69.
20. Masters CL, Richardson EPJ. Subacute spongiform encephalopathy (Creutzfeldt-Jakob disease): the nature and progression of spongiform change. Brain. 1978; 101:333-344.
21. Zerr I, Bodemer M, Räcker S, et al. Cerebrospinal fluid concentration of neuronspecific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 1995;345: 1609-1610.
22. Kretzschmar HA. Human prion diseases (spongiform encephalopathies). Arch Vlrol Suppl. 1993;7:261-293.
23. Hackler R, Schafer JR, Motzny S, et al. Rapid determination of apolipoprotein E phenotypes from whole plasma by automated isoelectric focusing using Phast-System and immunofixation. J Lipid Res. 1994;35:153-158.
24. Carlsson J, Armstrong VW, Reiber HO, Felgenhauer K, Seidel D. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chim Acta. 1991;196:167-176.
25. Gerdes LU, Klausen IC, Sihm I, Faergeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet Epidemiol. 1992;9:155-167.
26. Tiret L, de-Knijff P, Menzel HJ, Ehnholm C, Nicaud V, Havekes LM. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations: the EARS Study: European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol. 1994;14:1617-1624.
27. Lehtimaki T, Moilanen T, Viikari J, et al. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res. 1990; 31:487-495.
28. Rebeck GW, Perls TT, West HL, Sodhi P, Lipsitz LA, Hyman BT. Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology. 1994;44:1513-1516.
29. Yanagi H, Shimakura Y, Yamanouchi Y, Watanabe Y, Tsuchiya S, Hamaguchi H. Association of hypercholesterolemia and apolipoprotein E4 in school children. Clin Genet. 1990;38:264-269.
30. Kim YS, Paeng JR, Woo JT, et al. Apolipoprotein E genotypes of normal and hyperlipidemic subjects. J Korean Med Sci. 1993;8:262-266.
31. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993; 11:575-580.
32. Blennow K, Hesse C, Fredman P. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport. 1994;5:2534-2536.
33. Lehtimaki T, Pirttila T, Mehta PD, Wisniewski HM, Frey H, Nikkari T. Apolipoprotein E (ApoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet. 1995;95:39-42.
34. Rösler N, Wichart I, Jellinger KA. Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immuoreactive apolipoprotein E in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996;60: 452-454.
35. Jimi T, Wakayama Y, Shibuya S, et al. High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta. 1992;211:37-46.
36. Han SH, Einstein G, Weisgraber KH, et al. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol. 1994;53:535-544.
37. Doi-Yi R, Kitamoto T, Ogomori K, Mehraein P, Tateishi J. Distribution of prion protein in German patients with Creutzfeldt-Jakob disease is different from that in Japanese patients. Acta Neuropathol (Berl). 1994;87:481-483.